A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

(HealthDay News) — For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MIDAS) scores, according ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Joining the ranks of Viagra, Xanax, and Botox, a new superstar has emerged: Ozempic. Ozempic, along with its sister drug Wegovy, belongs to a new class of therapeutic known as GLP-1 receptor agonists.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...